NewGenIvf’s acquired IP valued at $17.9 million, boosts NAV

BANGKOK - NewGenIvf Group Limited (NASDAQ:NIVF), a fertility services provider with a current market capitalization of $1.59 million and trailing twelve-month revenue of $5.43 million, announced Monday that an independent valuation report from a Big Four global accounting firm has set the fair value of its recently acquired cytometry intellectual property at $17.9 million. According to InvestingPro analysis, the company currently operates with significant debt challenges and faces cash burn concerns.

The valuation of the IP, which was acquired on July 29, 2025, has resulted in a bargain purchase gain of $19.2 million for the company, increasing NewGenIvf’s net asset value by approximately $8.9 per share, according to the company’s press release statement. With a current ratio of 1.17 and negative EBITDA of -$1.14 million, this acquisition represents a significant development for the company’s balance sheet structure.

The IP is associated with advanced cytometry technology equipment that was also part of the acquisition. NewGenIvf stated that this acquisition represents a strategic shift from traditional IVF services to becoming a technology-driven service provider.

The company plans to generate revenue through licensing the technology, collecting royalty fees, and supplying proprietary consumables to fertility service clinics. NewGenIvf is currently pursuing regulatory approvals to commercialize the technology.

"This transaction demonstrates our team’s ability to identify and execute on highly accretive opportunities in the fertility technology sector," said Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGenIvf.

NewGenIvf operates fertility clinics in Thailand, Cambodia, and Kyrgyzstan, offering services including assisted reproductive technology treatments, egg and sperm donation, and surrogacy in appropriate jurisdictions.

The company expects the bargain purchase gain to significantly enhance its net profit in its year-end financial results. For investors seeking deeper insights into NIVF’s valuation metrics and financial health indicators, InvestingPro offers comprehensive analysis with 13 additional ProTips and advanced valuation tools to help evaluate the company’s future prospects.

In other recent news, NewGenIvf Group Limited has made significant strides with several strategic moves. The company announced the acquisition of cytometry technology and assets, including 18 fully-constructed cell-sorting systems, eight partially constructed units, and six patents. This acquisition aims to enhance their presence in the US fertility market, building on their previous purchase of MicroSort technology, now known as NewGenSort. Additionally, NewGenIvf’s subsidiary, NewGenDigital, has entered a memorandum of understanding with BNW Real Estate Development LLC to jointly develop a plot in Ras Al Khaimah’s Beach District, with NewGenDigital contributing $24 million toward the initial land cost.

In corporate governance developments, NewGenIvf’s board of directors has approved a reverse stock split and an amendment to its memorandum and articles of association. This amendment increases the number of authorized shares from a maximum of 50,000,000 to an unlimited number, including various classes of ordinary and preferred shares. The amendment was filed and became effective on July 4. These recent developments indicate NewGenIvf’s proactive approach to expanding its technological capabilities and market reach while also optimizing its corporate structure.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.